Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...

Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.

A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful ...

A NEW weight loss jab that only needs to be taken once monthly leads to “substantial weight loss”, according to early trials.

The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...

Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...

US biotech major Amgen, a late comer to the growing obesity treatment space, released new data showing that its MariTide ...

Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...

Amgen Inc. (NASDAQ:AMGN) is one of the 11 stocks Jim Cramer put under the microscope recently. Cramer highlighted Wall Street’s reaction to the company’s latest data announcement regarding MariTide, ...

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...

Amgen's experimental drug MariTide shows potential for significant weight loss in obese patients, despite notable side ...